Genor Biopharma Holdings Limited (HK:6998) has released an update.
Genor Biopharma Holdings Limited has announced an important license agreement with TRC 2004, Inc. for the exclusive global rights (excluding greater China) to develop and commercialize GB261, a promising novel treatment for autoimmune diseases and B-NHL. The deal includes equity in TRC 2004, an upfront payment in the double-digit millions, potential milestone payments up to $443 million, and royalties on net sales. This collaboration harnesses the Licensee’s expertise in advancing therapeutic technologies, furthering Genor Biopharma’s mission to address unmet medical needs in oncology and immunology.
For further insights into HK:6998 stock, check out TipRanks’ Stock Analysis page.